Investor Presentaiton
Important updates today
Expanding Currently
Launched Products
Sotyktu:
Impressive Ph2 SLE data supports
Ph3 programs in SLE & SjS
Abecma:
- KarMMa-3 under regulatory review
in triple class exposed population
KarMMa-9 registrational trial in
post-transplant MM initiating
this year
Subcutaneous nivolumab:
- Potential to benefit patients into
early 2030's with data anticipated
this year
Camzyos:
Data suggests myosin inhibitors
remodel the heart
New Wave of NME
LPA₁ Antagonist:
Demonstrated compelling Ph2 PPF data and Ph3 studies initiating
CD19 NEX T:
- Ph 1 study initiated in severe, refractory lupus with promise to reset
the immune system & expanding into other immunologic diseases
BET Inhibitor (BMS-986158):
Proof-of-concept data expected early next year
GPRC5D CAR T:
-
Differentiated profile addressing unmet need post-BCMA targeting
treatment; initiating pivotal trial next year
alnuctamab:
-
- Initiating Ph3 trial in 2024 in MM
iberdomide/mezigdomide:
- Ph3 data expected in 2026
golcadomide:
Initiating Ph3 trial in 2024 in 1L LBCL
AR LDD:
Significant opportunity in mCRPC with data expected early next year
- Initiating pivotal trial in the next 18 months
milvexian:
Compelling rationale for Ph3 programs
•
•
Early Assets to Watch
BCMA X GPRC5D:
Entering into POC soon
BCL6 LDD:
Novel oral degrader in lymphomas
TIGIT Bispecific:
- Differentiated IO; targeting TIGIT &
CD96
DGK inhibitor:
Potential transformational oral, dual
inhibitor
Anti-CCR8:
Treg depleting mAb therapy with broad
combination potential
Advancing Neuro PoC trials in 2024:
Anti-MTBR-Tau in Alzheimer's Disease
elF2B Activator in ALS
TYK2i CNS (pre-clinical):
Moving into clinic soon, targeting MS
MYK-224:
Progressing into HFPEF
O
Increasing registrational assets
from 6 to 12 in next 18 months
ll Bristol Myers Squibb™
Increase INDs to at
-10 per year
Productivity
о
Increase to -20% POS
from FIH to approval
Achieve median -6.5
years from FIH to approval
Not for Product Promotional Use
134View entire presentation